REGENXBIO (RGNX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

REGENXBIO Revenue Highlights


Latest Revenue (Y)

$90.24M

Latest Revenue (Q)

$24.20M

Main Segment (Y)

License and Service

REGENXBIO Revenue by Period


REGENXBIO Revenue by Year

DateRevenueChange
2023-12-31$90.24M-19.94%
2022-12-31$112.72M-76.03%
2021-12-31$470.35M204.30%
2020-12-31$154.57M338.70%
2019-12-31$35.23M-83.88%
2018-12-31$218.50M2002.42%
2017-12-31$10.39M126.48%
2016-12-31$4.59M-39.52%
2015-12-31$7.59M23.99%
2014-12-31$6.12M0.54%
2013-12-31$6.09M-

REGENXBIO generated $90.24M in revenue during NA 2023, up -19.94% compared to the previous quarter, and up 41.30% compared to the same period a year ago.

REGENXBIO Revenue by Quarter

DateRevenueChange
2024-09-30$24.20M8.53%
2024-06-30$22.30M42.72%
2024-03-31$15.62M-29.67%
2023-12-31$22.21M-23.18%
2023-09-30$28.91M44.74%
2023-06-30$19.98M4.38%
2023-03-31$19.14M-38.94%
2022-12-31$31.34M18.23%
2022-09-30$26.51M-18.80%
2022-06-30$32.65M46.95%
2022-03-31$22.22M-94.43%
2021-12-31$398.65M1195.47%
2021-09-30$30.77M39.66%
2021-06-30$22.04M16.69%
2021-03-31$18.88M-11.94%
2020-12-31$21.45M-78.32%
2020-09-30$98.91M497.08%
2020-06-30$16.57M-6.11%
2020-03-31$17.64M49.93%
2019-12-31$11.77M-19.95%
2019-09-30$14.70M86.52%
2019-06-30$7.88M791.52%
2019-03-31$884.00K-97.83%
2018-12-31$40.78M668.51%
2018-09-30$5.31M-86.75%
2018-06-30$40.03M-69.76%
2018-03-31$132.39M6389.75%
2017-12-31$2.04M52.69%
2017-09-30$1.34M-79.64%
2017-06-30$6.56M1342.20%
2017-03-31$455.00K-73.17%
2016-12-31$1.70M1256.80%
2016-09-30$125.00K-94.74%
2016-06-30$2.38M504.33%
2016-03-31$393.00K-91.16%
2015-12-31$4.45M290.18%
2015-09-30$1.14M-16.36%
2015-06-30$1.36M111.65%
2015-03-31$644.00K-43.90%
2014-12-31$1.15M137.68%
2014-09-30$483.00K-

REGENXBIO generated $24.20M in revenue during Q3 2024, up 8.53% compared to the previous quarter, and up 121.12% compared to the same period a year ago.

REGENXBIO Revenue Breakdown


REGENXBIO Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
License and Service$90.24M$112.72M---
License And Service--$470.35M$154.57M-
License----$3.50M
Zolgensma Royalties----$20.83M

REGENXBIO's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
License and Service$24.20M$22.30M$15.62M$70.27M$19.98M$31.34M--------------
License And Service-----$19.14M$26.51M$32.65M$22.22M$398.65M$30.77M$22.04M$18.88M-------
Zolgensma Royalties--------------$20.91M$18.80M$11.95M$9.98M$10.72M-
License----------------$3.50M$3.50M--
Achievement Of Sales Based Milestone For Zolgensma---------------$80.00M----

REGENXBIO's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License and Service (100.00%).

REGENXBIO Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
IMCRImmunocore$249.43M$75.40M
MIRMMirum Pharmaceuticals$186.37M$77.88M
RGNXREGENXBIO$90.24M$24.20M
PTGXProtagonist Therapeutics$60.00M$4.67M
QUREuniQure$15.84M$2.29M
RVMDRevolution Medicines, Inc. Warrant$11.58M-
RNAAvidity Biosciences$9.56M$2.04M
STOKStoke Therapeutics$8.78M$4.89M
KZRKezar Life Sciences$7.00M-
CRNXCrinetics Pharmaceuticals$4.01M-
PLRXPliant Therapeutics$1.58M-
LIANLianBio--
ANTXAN2 Therapeutics--
DAWNDay One Biopharmaceuticals-$20.07M
REPLReplimune Group--
RCKTRocket Pharmaceuticals--
PASGPassage Bio--
GLUEMonte Rosa Therapeutics-$4.70M
FDMT4D Molecular Therapeutics--

RGNX Revenue FAQ


What is REGENXBIO’s yearly revenue?

REGENXBIO's yearly revenue for 2023 was $90.24M, representing a decrease of -19.94% compared to 2022. The company's yearly revenue for 2022 was $112.72M, representing a decrease of -76.03% compared to 2021. RGNX's yearly revenue for 2021 was $470.35M, representing an increase of 204.30% compared to 2020.

What is REGENXBIO’s quarterly revenue?

REGENXBIO's quarterly revenue for Q3 2024 was $24.2M, a 8.53% increase from the previous quarter (Q2 2024), and a -16.31% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $22.3M, a 42.72% increase from the previous quarter (Q1 2024), and a 11.60% increase year-over-year (Q2 2023). RGNX's quarterly revenue for Q1 2024 was $15.62M, a -29.67% decrease from the previous quarter (Q4 2023), and a -18.37% decrease year-over-year (Q1 2023).

What is REGENXBIO’s revenue growth rate?

REGENXBIO's revenue growth rate for the last 3 years (2021-2023) was -80.81%, and for the last 5 years (2019-2023) was 156.13%.

What are REGENXBIO’s revenue streams?

REGENXBIO's revenue streams in c 23 are License and Service

What is REGENXBIO’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of REGENXBIO was License and Service. This segment made a revenue of $90.24M, representing 100.00% of the company's total revenue.